JPT Peptide Technologies posted this:Custom Peptide SynthesisJPT Peptide Technologies has a substantial, long-standing expertise in custom peptide synthesis services, providing custom peptides with highest quality for even complex or unusual peptide sequences. If you would like to order a quality peptide synthesis service using regulated processes, choose JPT! Furthermore, our peptide synthesis service has a very high success rate (over 99%) as JPT has developed the know-how to choose and optimize the appropriate synthesis method for each peptide. We go the extra mile to get your peptides done!
Creative Proteomics posted this:Proteomic ServiceCreative Proteomics specializes in a full range of services to support various proteome-related researches from identification of single proteins to large-scale proteomic studies. We have one of the most advanced proteomics platforms in the world and our staff scientists are experienced proteomics professionals.
Research InstituteView Profile
Germans Trias i Pujol Health Sciences Research Institute posted this:Innovative device for electro-mechanical stimulation for tissue engineering applicationsThe device presented enables the combination of both electrical and mechanical stimulation either independently or simultaneously. The mechanical stimulation is performed with a non-invasive and aseptic novel approach. A sterile, single use device is placed into a standard culture plate. The cells are seeded in a volume contained in the central area of the device, which goes through mechanical stimulation thanks to the embedded magnets and the external magnetic field.
Creative Proteomics posted this:2,6-DIBDE (BDE-10) 50 UG/ML IN NONANE UNLABELED CERTIFIED STANDARDCreative Proteomics provides a full range of drug development services, including Molecular Biology, Biochemistry, Systems Biology, Organic Chemistry, Genomics, Bioinformatics, Structural Biology, Preclinical and Clinical studies. Please contact us to know more about 2,6-DIBDE (BDE-10) 50 UG/ML IN NONANE UNLABELED CERTIFIED STANDARD!
Creative Peptides posted this:Catalog Peptides-Teduglutide cas 197922-42-2Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We offer custom peptide synthesis, process development, GMP manufacturing as well as catalog products. We provide Teduglutide. More information please visit the website:http://www.creative-peptides.com/product/teduglutide-item-m3412132-21367.html
RAMOT at Tel Aviv University Ltd. posted this:Novel Anti Bacterial DrugTwo non-toxic short peptides were conjugated to form a novel drug candidate. One of the peptides is a polymyxin-B or polymyxin-E analog (PMBN or PMEN, respectively) while the other is an immune cell chemotactic peptide (fMLF). The resultant new drug candidates (PMBN-fMLF or PMEN-fMLF) exhibit three antimicrobial activities: (a) it binds specifically to gram negative bacteria, thus enhancing penetration of antibiotics into the bacteria and (b) it promotes bacterial killing by blood phagocytes and (c) It binds to free LPS in the blood thus reduces effect on patients. Project ID : 10-2007-98
RAMOT at Tel Aviv University Ltd. posted this:GSK-3 Peptide Inhibitors for the Treatment of CNS Related DisordersNovel Glycogen synthase kinase 3 (GSK-3) inhibitors were developed. These inhibitors are substrate competitors that interact specifically with the GSK-3 substrate binding site. GSK-3, like other protein kinases, has a common structurally conserved catalytic domain that comprises the ATP-binding loop. The great majority of reported inhibitors developed to date are ATP-competitive compounds; however, such inhibitors demonstrate limited specificity, as the ATP-binding pocket is highly conserved among protein kinases. In contrast, the substrate binding site is more specific, and thus targeting inhibitors toward this domain yields more specific compounds. The strategy is based on exploiting the unique recognition motif of GSK-3 which comprises a phosphorylated residue and using molecular and computational analyses. Project ID : 10-2011-132
RAMOT at Tel Aviv University Ltd. posted this:Improved Calcitonin-based TherapeuticsThe aggregation site on human calcitonin has been identified, paving the way for development of specific inhibitors of calcitonin amyloid fibril formation. Such inhibitors will enable development of improved calcitonin therapeutics as well as greatly facilitate in vitro calcitonin manipulations. Project ID : 10-2007-103
RAMOT at Tel Aviv University Ltd. posted this:Novel markers for the identification and isolation of stem and progenitor cellsA series of novel markers: (1) chromatin remodeling protein factor termed (CHD9/CReMM), (2) A cell adhesion protein termed (SVEP1), (3) A kinesin protein termed (MS-KIF18A), (4) RNA processing factor (SRRF/hNRNP-L) have been developed as novel markers for the identification and isolation of stem and progenitor cells. Project ID : 10-2007-104
RAMOT at Tel Aviv University Ltd. posted this:Targeted filamentous bacteriophages as therapeutic agentsTargeted drug-carrying filamentous bacteriophages have been developed as a novel therapeutic approach for the treatment of infectious disease and cancer. The phages are genetically-modified to display an antibody or a targeting peptide as a targeting moiety on their surface and are used to deliver a cytotoxic drug to the target. The drug is linked to the phages by means of chemical conjugation through a labile linker subject to controlled release. In the conjugated state the cytotoxic drug is devoid of cytotoxic activity and is activated following its dissociation from the targeting phage at the target site in a temporally and spatially controlled manner. Project ID : 2-2008-23
RAMOT at Tel Aviv University Ltd. posted this:Novel ALS biomarkers:Towards diagnostics and potential therapyWe have identified ALS-specific biomarker candidate genes that are differentially expressed in blood and bone marrow samples from ALS patients. These biomarkers can be used for ALS diagnosis. Most importantly, these biomarkers can be used as targets for screening and identifying lead compounds for the treatment of ALS. Project ID : 10-2009-82
RAMOT at Tel Aviv University Ltd. posted this:Quinone-based small molecules as a novel therapy for Alzheimer's disease and AmyloidosisDisease modifying drugs for Alzheimer's disease (AD) and the related Mild Cognitive Impairment (MCI), based on rationally-designed quinone-based small molecules. Results so far resulted in significant reversal of AD symptoms while causing no apparent adverse effects. Project ID : 10-2011-181